Pharmaceuticals
Xinhua Silk Road: Activity to promote TCM cultural exchanges and cooperation between China and Luxembourg completes success
BEIJING, June 1, 2023 /PRNewswire/ -- An activity to promote traditional
Chinese medicine (TCM) cultural exchanges and cooperation betweenChina and
Luxembourg held recently at the Luxembourg Embassy in China achieved a complete
success.
2023-06-01 17:37
2040
Xinhua Silk Road: Chinese Lingzhi brand Longevity Valley promotes inheritance of a century-old national treasure to Brunei foreign envoys
BEIJING, May 31, 2023 /PRNewswire/ -- A delegation of the renowned Chinese Lingzhi brand, Zhejiang Longevity Valley Botanical Co., Ltd, recently visited the Embassy ofBrunei Darussalam in China to showcase Chinese traditional culture and wisdom of health philosophy embedded in the brand toBrunei....
2023-06-01 09:47
2240
Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer's Disease Phase 2 trials at the BIO International Convention
Xanamem® is an oral, brain-penetrant tissue cortisol synthesis inhibitor that has shown promising safety and clinical activity in three placebo-controlled trials and has the potential to treat a variety of neurodegenerative and neuropsychiatric diseases SYDNEY, May 31, 2023 /PRNewswire/ -- Actin...
2023-05-31 20:58
2275
QBIOTICS TO PRESENT AT SACHS 9TH ANNUAL IMMUNO-ONCOLOGY INNOVATION FORUM AND THE BIO INTERNATIONAL CONVENTION
BRISBANE, Australia, May 31, 2023 /PRNewswire/ -- QBiotics Group Limited ( QBiotics), a clinical stage life sciences company developing novel small molecule anticancer and wound healing pharmaceuticals is pleased to announce thatRichard Godfrey will present to potential partners and investors at t...
2023-05-31 19:00
2726
Asieris' progress in MIBC receives renewed attention with its inclusion in ASCO 2023
SHANGHAI, May 31, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176)， a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced the phase I clinical data of ANTICIPATE ...
2023-05-31 16:00
1830
Ascentage Pharma's Novel Drug Olverembatinib Recommended for a Breakthrough Therapy Designation in China for the Treatment of SDH-Deficient GIST, the Second BTD for the Drug
SUZHOU, China and ROCKVILLE, Md., May 30, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announcedtoday that the Center for Drug Evaluation (CDE) of China Na...
2023-05-31 10:20
1948
iNtRON identifies Prophage and Jamphage in the Pancreatic cancer related Microbiome
* It was confirmed the presence of Prophage and Jamphage in the Alkalihalobacillus clausii * Prophage and Jamphage are expected to play a substantial role in bacterial survival and immune regulation in the body. BOSTON and SEOUL, South Korea, May 29, 2023 /PRNewswire/ -- iNtRON Biotechnology ...
2023-05-30 10:15
1837
AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer
HIGHLIGHTS * Amplia's highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic cancer * FOLFIRINOX is the most widely used treatment for pancreatic cancer patients in the US,Canada and most European countries * T...
2023-05-29 16:51
2952
Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023
* Porustobart in combination of toripalimab showed promising anti-tumor activity * Porustobart in combination of toripalimab showed acceptable safety profile in HCC * Porustobart in combination of toripalimab showed favorable PK/PD signature CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZH...
2023-05-29 09:42
2236
77.4% ORR! Abbisko to present the updated clinical phase Ib data of Pimicotinib (ABSK021) at the 2023 ASCO Annual Meeting
SHANGHAI, May 28, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that the updated results of Phase Ib study of its CSF-1R inhibitor Pimicotinib (ABSK021) in treating patients with advanced tenosynovial giant cell tumor ("TGCT"), will be rele...
2023-05-28 21:00
3005
ProfoundBio Announces Further Advancement of Lead Programs - PRO1184 (Rinatabart Sesutecan) and PRO1160 in the Clinic
* PRO1160 first patient dosed in the US * China NMPA clearance for PRO1184 (rinatabart sesutecan, Rina-S) and PRO1160 to initiate clinical trials * Rina-S preliminary clinical data is encouraging SUZHOU, China and WOODINVILLE, Wash., May 26, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage...
2023-05-26 20:00
2338
FivepHusion Announces Strategic Collaboration with Treehill Partners and Syneos Health
Supporting FivepHusion's Global Development and Commercialization Strategy SYDNEY, May 26, 2023 /PRNewswire/ -- FivepHusion, an advanced clinical-stage biotechnology company, today announced its collaboration with Treehill Partners, aNew York-based strategic and financial advisory firm specializi...
2023-05-26 13:42
2255
Ascentage Pharma Presents Updated Results from Multiple Clinical Studies at American Society of Clinical Oncology Annual Conference
SUZHOU, China, and ROCKVILLE, Md., May 25, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that 4 of its abstracts were selected for presenta...
2023-05-26 10:01
3184
Dizal's Oncology Pipeline Continues to Impress with Two Oral Presentations at 2023 ASCO Annual Meeting
SHANGHAI, May 25, 2023 /PRNewswire/ -- Dizal (688192.SH) today announced that data from its oncology portfolio will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting,June 2-6, 2023 in Chicago. The data which include updated analyses of Dizal's two leading assets...
2023-05-26 06:00
2213
Daewoong Pharmaceutical Publishes Molecular Mechanism of Bersiporocin as an Antifibrotic in EMBO Molecular Medicine
* Elucidated molecular mechanism behind safety and efficacy of Bersiporocin * Bersiporocin is currently in Phase II clinical trial for Idiopathic Pulmonary Fibrosis SEOUL, South Korea, May 25, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEOLee Chang-jae and Jeon Sengho) announced on the 25th...
2023-05-26 06:00
2357
I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023
- Uliledlimab is a differentiated monoclonal antibody designed to target CD73 and promote stronger activation ofpatients' immune system against cancer cells. - In newly diagnosed patients who were not eligible for or declined chemotherapy treatment, 63% of the patients with CD73High and PD-L1 T...
2023-05-26 05:01
2302
Hepagene Therapeutics to Present at the European Association for the Study of the Liver (EASL) Congress 2023
SHANGHAI, May 25, 2023 /PRNewswire/ -- Hepagene Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on developing novel therapies for patients with chronic liver diseases, today announced that Hepagene will present two posters highlighting the preclinical and clinical developm...
2023-05-25 22:00
2032
HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson's Disease
* HanAll Biopharma and Daewoong Pharmaceutical will co-develop NurrOn Pharmaceuticals' novel investigational compounds, including its lead asset ATH-399A, targeting Nurr1 for the treatment of Parkinson's disease (PD), as well as other neurodegenerative disorders * Phase 1 clinical trial is ex...
2023-05-25 19:00
2370
Telix to Host Briefing with U.S. Leadership Team and Key Opinion Leaders to Highlight Innovation in Urology
June 21, 2023, at The Yale Club, New York City The Company will showcase its urologic pipeline, development of novel therapeutics, imaging agents and technologies that aim to harness the power of targeted radiation at every step of the patient journey MELBOURNE, Australia and INDIANAPOLIS, May 2...
2023-05-25 19:00
2014
111 to Announce First Quarter 2023 Unaudited Financial Results on June 15, 2023 - Conference Call to Follow
SHANGHAI, May 25, 2023 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results ...
2023-05-25 14:05
1978
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7433
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
6834
